MaxCyte, Inc. (MXCT) Stock Forecast
MXCT analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.67 / 5 from 6 analysts
- Price target
- $4.11 average of analyst targets
- Upside to target
- +216.0% from the latest close
- Next earnings
- November 10, 2026 EPS estimate $-0.08
- 52-week range
- $0.68 – $1.76
MXCT analyst ratings
6 analystsNumber of analysts at each rating.
MXCT price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
MXCT earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.08 | −$0.09 | −$0.08 | −$0.09 | +5.1% | 3 |
| Current fiscal year (2026) | −$0.28 | −$0.30 | −$0.25 | −$0.36 | +22.5% | 3 |
| Next fiscal year (2027) | −$0.25 | −$0.28 | −$0.19 | −$0.28 | +10.8% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
MXCT revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $7.5M | $6.9M | $9.5M | +9.4% | 5 |
| Current fiscal year (2026) | $32.2M | $30.9M | $34.3M | −2.5% | 6 |
| Next fiscal year (2027) | $37.2M | $34.9M | $38.8M | +15.5% | 6 |
MXCT EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
MXCT revenue: reported and forecast
MXCT EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.07 | −$0.08 | −$0.08 | −$0.08 | −$0.08 | +11.1% | 0 up · 1 down |
| Current fiscal year (2026) | −$0.28 | −$0.27 | −$0.28 | −$0.28 | −$0.28 | +0.6% | 1 up · 3 down |
| Next fiscal year (2027) | −$0.23 | −$0.24 | −$0.25 | −$0.25 | −$0.25 | +5.0% | 1 up · 3 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
MXCT earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; MXCT beat in 10 of 12.
What analysts expect from MXCT
6 analysts cover MaxCyte; their consensus rating is strong buy (4.67 on a 1–5 scale, where 5 is a strong buy). The average price target is $4.11, 216.0% above the latest close of $1.30. Analysts expect earnings of −$0.28 per share for 2026, +22.5% from a year earlier. For 2027 the average estimate is −$0.25 per share on revenue of $37.2 million. MaxCyte beat the EPS estimate in 10 of the last 12 quarters.
Related: MXCT income statement, MXCT key metrics, MXCT chart. See the MXCT stock overview for the latest quote and news.
MXCT forecast FAQ
What is MaxCyte's price target?
The average analyst price target for MaxCyte is $4.11, 216.0% above the latest close of $1.30.
Is MaxCyte a buy, hold or sell?
Of 6 analysts covering MaxCyte, 5 rate it a strong buy, 0 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is MaxCyte's EPS forecast?
Analysts forecast −$0.28 per share for 2026 (range −$0.30 to −$0.25); for 2027 the estimate is −$0.25.
What is MaxCyte's revenue forecast?
The average revenue estimate for 2026 is $32.2 million, growth of −2.5%; for 2027 it is $37.2 million.
When does MaxCyte report earnings?
MaxCyte is expected to report results for the quarter ending September 30, 2026 on November 10, 2026 after the market closes; the EPS estimate is $-0.08.
Does MaxCyte usually beat earnings estimates?
MaxCyte reported EPS at or above the analyst estimate in 10 of the last 12 quarters.